Person:
ARICI, DILEK SEMA

Profile Picture
Google ScholarScopusORCIDPublons
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
DILEK SEMA
Last Name
ARICI
Name
Email Address
Birth Date

Filters

Browse subject tree
2014 - 20152
Reset filters

Settings

Author: Arici, Sema × Author: Ince, ALİ TÜZÜN × Author: BAYSAL, Birol ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Primary pancreatic lymphoma is a rare cause of pancreatic mass: A case report
    (2015-09-01) BAYSAL, Birol; KAYAR, Yusuf; Ince, ALİ TÜZÜN; Arici, Sema; TURKMEN, Ihsan; Senturk, HAKAN; İNCE, ALİ TÜZÜN; ARICI, DILEK SEMA; ŞENTÜRK, HAKAN
    Primary pancreatic lymphoma (PPL) is a rare entity, most likely to be clinically misdiagnosed as pancreatic cancer. The cure rate of PPL is higher compared with that of pancreatic adenocarcinoma. This is the case report of a 57-year-old male patient who was hospitalized with complaints of abdominal pain, weight loss and jaundice. The radiological evaluation revealed a pancreatic head mass and, following endoscopic ultrasound-guided fine-needle aspiration biopsy, the tumor was diagnosed as diffuse large B-cell lymphoma. The final diagnosis was PPL, and the patient went into remission after receiving three cycles of treatment with rituximab, doxorubicin, cyclophosphamide, vincristine and prednisolone (R-CHOP regimen). Therefore, PPL should be considered in the differential diagnosis of pancreatic masses and its management differs from that of other types of pancreatic tumor.
  • No Thumbnail Available
    PublicationMetadata only
    Yields of Dual Therapy Containing High-Dose Proton Pump Inhibitor in Eradication of H. Pylori Positive Dyspeptic Patients
    (2014-07-01) Ince, ALİ TÜZÜN; TOZLU, Mukaddes; BAYSAL, Birol; Senturk, HAKAN; Arici, Sema; Ozden, Ali; İNCE, ALİ TÜZÜN; ŞENTÜRK, HAKAN; ARICI, DILEK SEMA
    Background/Aims: H. pylon eradication has been recommended for dyspeptic patients in high prevalance regions. Triple therapies are still prescribed mostly because culture and antibiotic susceptibility tests aren-t widely available in the world. Dual therapy with high-dose proton pump inhibitors reported to have higher eradication rates. Our objective was to determine eradication success and cost-effectivity of dual therapy in dyspeptic patients. Methodology: Patients were treated orally with either dual (n:74,omeprazole 20mg q.i.d and amoxicillin 1g b.i.d) or triple therapy (n:116,omeprazole 20mg b.i.d and amoxicillin 1g b.i.d and clarithromycin 500mg b.i.d) for 14 days. HpSA was requested 3 months later. The results were evaluated statistically, p values <0,05 were considered significant. Results: Patients (n:190) were included the study((80 female,110 male, mean age: 35.6 11yearr). Alcohol/smoking, endoscopic findings and H. pylon rates with pathological examinations were not significantly different between groups whereas there was significant difference in HpFast tests(p<0.01). Whe examined with HpSA tests 3 months after the treatment eradication rate was 81.1% in the dual therapy group versus 63.8% in the triple therapy group (p:0.011) Dual therapy was economic than triple therapy (144USDvs.107USD,p<0.001). Conclusions: Dual therapy seems more successful cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia.